G-FINDER data portal: tracking funding for global health R&D

The G-FINDER project tracks R&D funding for new products and technologies that address global health challenges disproportionately affecting the world's most disadvantaged populations. The G-FINDER data portal provides open access to all data captured by the G-FINDER project between 2007 and 2021 and is updated annually at the start of the year.

or select a quick filter:

Policy Cures Research uses the data captured by the G-FINDER project to produce a range of independent reports, including the G-FINDER neglected diseases, emerging infectious diseases, and sexual & reproductive health reports. Please include the following reference when citing or using text, figures, or data from this site:
Policy Cures Research, G-FINDER data portal, https://gfinderdata.policycuresresearch.org

* Note: these values differ slightly from the figures presented in our new report on funding for sexual & reproductive health R&D. This is a result of adjustments to the Portal data based on updated information.

Distribution of funding across these STIs has remained relatively constant, with gonorrhoea receiving by far the most funding

Historically, around half of HPV R&D funding has gone to vaccines, and around a quarter to diagnostics

The peaks and troughs in MPT funding have been largely driven by changes in industry investment

While long-acting reversible contraception (LARC) funding decreased for the third consecutive year in FY21, it still accounted for 45% of total contraceptive funding

While funding for non-maternal heath SRH R&D has grown, investment in maternal health issues has declined